{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "research-program", "type": "definition", "offset": [11, 27]}, {"key": "active-compounds", "type": "clause", "offset": [28, 44]}, {"key": "the-foregoing", "type": "clause", "offset": [331, 344]}, {"key": "licensed-compound", "type": "definition", "offset": [349, 366]}], "snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "samples": [{"hash": "cBlQ6dTV8Mr", "uri": "/contracts/cBlQ6dTV8Mr#licensed-compounds", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "mNHm0OY40j", "uri": "/contracts/mNHm0OY40j#licensed-compounds", "label": "Collaboration Agreement (Discovery Partners International Inc)", "score": 21.0, "published": true}, {"hash": "i3bRX4mtKZe", "uri": "/contracts/i3bRX4mtKZe#licensed-compounds", "label": "Collaboration Agreement (Infinity Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "size": 6, "hash": "c4d28c485812e816983f87e5c8418347", "id": 1}, {"snippet_links": [{"key": "in-combination", "type": "definition", "offset": [85, 99]}, {"key": "purpose-of-use", "type": "definition", "offset": [135, 149]}, {"key": "licensed-product", "type": "definition", "offset": [153, 169]}, {"key": "in-the-field", "type": "clause", "offset": [194, 206]}, {"key": "in-the-territory", "type": "clause", "offset": [207, 223]}], "snippet": "means the antiretroviral compounds known as lopinavir and ritonavir, individually or in combination, manufactured or sold for the sole purpose of use in Licensed Product solely for Exploitation in the Field in the Territory.", "samples": [{"hash": "UZK1t2cl9T", "uri": "/contracts/UZK1t2cl9T#licensed-compounds", "label": "License Agreement", "score": 35.3694419861, "published": true}, {"hash": "kE8pjttLRi6", "uri": "/contracts/kE8pjttLRi6#licensed-compounds", "label": "License Agreement", "score": 28.6865272522, "published": true}, {"hash": "ci96oYIbTyR", "uri": "/contracts/ci96oYIbTyR#licensed-compounds", "label": "License Agreement", "score": 28.5031242371, "published": true}], "size": 5, "hash": "8c440d371863270d27c2fdfd598b12dd", "id": 2}, {"snippet_links": [{"key": "by-either-party", "type": "clause", "offset": [66, 81]}, {"key": "respective-affiliates", "type": "definition", "offset": [100, 121]}, {"key": "third-party", "type": "definition", "offset": [129, 140]}, {"key": "working-with", "type": "definition", "offset": [141, 153]}, {"key": "such-party", "type": "clause", "offset": [170, 180]}, {"key": "of-the-parties", "type": "clause", "offset": [245, 259]}, {"key": "conduct-of-the-collaboration", "type": "clause", "offset": [267, 295]}, {"key": "exercise-of", "type": "clause", "offset": [306, 317]}, {"key": "this-agreement", "type": "clause", "offset": [346, 360]}, {"key": "prior-agreement-effective-date", "type": "definition", "offset": [380, 410]}, {"key": "target-exclusivity-period", "type": "definition", "offset": [526, 551]}, {"key": "at-any-time", "type": "clause", "offset": [636, 647]}, {"key": "prior-to-the", "type": "clause", "offset": [659, 671]}], "snippet": "means any EZH2 Compound(s) that is:\n(a) synthesized or identified by either Party (or by any of its respective Affiliates or any Third Party working with or on behalf of such Party or any of its respective Affiliates) or jointly by or on behalf of the Parties in the conduct of the Collaboration or in the exercise of such Party\u2019s licenses under this Agreement from and after the Prior Agreement Effective Date, excluding Compounds Controlled by either Party and first identified as EZH2 Compounds after the expiration of the Target Exclusivity Period; or\n(b) otherwise Controlled by EPIZYME as of the Prior Agreement Effective Date or at any time thereafter prior to the expiration of the Target Exclusivity Period.", "samples": [{"hash": "9m7ph8xgnbN", "uri": "/contracts/9m7ph8xgnbN#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 32.1457901001, "published": true}, {"hash": "1dS7TxoQ6Hg", "uri": "/contracts/1dS7TxoQ6Hg#licensed-compounds", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "ew6NIZCekN6", "uri": "/contracts/ew6NIZCekN6#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 26.201915741, "published": true}], "size": 5, "hash": "e1a054699ffba7ee01317a64e2cbbcd8", "id": 3}, {"snippet_links": [{"key": "covered-by", "type": "definition", "offset": [22, 32]}, {"key": "patent-rights", "type": "clause", "offset": [65, 78]}], "snippet": "means those compounds covered by the Licensed ------------------ Patent Rights.", "samples": [{"hash": "kTLHE0epyOu", "uri": "/contracts/kTLHE0epyOu#licensed-compounds", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "aWgb3DDt35L", "uri": "/contracts/aWgb3DDt35L#licensed-compounds", "label": "Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 5, "hash": "8762b7b1f742fae978689f7aa87b1f1e", "id": 4}, {"snippet_links": [{"key": "lead-compound", "type": "definition", "offset": [14, 27]}, {"key": "collaboration-compounds", "type": "definition", "offset": [121, 144]}], "snippet": "means (a) the Lead Compound, (b) any Licensed Prothena Compounds, (c) any Licensed Roche Compounds, and (d) any Research Collaboration Compounds. [*]", "samples": [{"hash": "da9aBQllr7S", "uri": "/contracts/da9aBQllr7S#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.42710495, "published": true}, {"hash": "jWF7rQ6VTwU", "uri": "/contracts/jWF7rQ6VTwU#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.1779594421, "published": true}, {"hash": "30Bxs4KpB8O", "uri": "https://s29.q4cdn.com/936209790/files/doc_financials/2013/q4/0001559053-14-000007.pdf", "label": "s29.q4cdn.com", "score": 9.9637231827, "published": false}], "size": 4, "hash": "eda5353f591f28a9f18ad14149d8bcb4", "id": 5}, {"snippet_links": [{"key": "the-foregoing", "type": "clause", "offset": [339, 352]}], "snippet": "means (i) JCN068, (ii) any Back-up Compounds, and (iii) all prodrugs, metabolites, stereoisomers, diastereomers, enantiomers, tautomers, solvates, hydrate forms, homologs, salt forms, labeled forms (e.g., deuterated, 13C enriched, etc.), esters, crystalline forms (e.g., polymorphs), semi-crystalline forms, and amorphous forms, of any of the foregoing compounds.", "samples": [{"hash": "knxU6sgGxaf", "uri": "/contracts/knxU6sgGxaf#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 33.2245025635, "published": true}, {"hash": "4gJRxMjC6ka", "uri": "/contracts/4gJRxMjC6ka#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4798088074, "published": true}, {"hash": "f5QS7bHrhFY", "uri": "/contracts/f5QS7bHrhFY#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4360046387, "published": true}], "size": 4, "hash": "b3f0b895e6931677cb8b6b24c3bfba46", "id": 6}, {"snippet_links": [{"key": "offer-for-sale", "type": "definition", "offset": [61, 75]}, {"key": "covered-by", "type": "definition", "offset": [94, 104]}, {"key": "university-technology", "type": "definition", "offset": [109, 130]}, {"key": "claims-of", "type": "clause", "offset": [155, 164]}, {"key": "the-patents", "type": "clause", "offset": [165, 176]}], "snippet": "means any individual compounds whose manufacture, use, sale, offer for sale or importation is covered by any University Technology or by one or more Valid Claims of the Patents.", "samples": [{"hash": "fFBugrmCrSK", "uri": "/contracts/fFBugrmCrSK#licensed-compounds", "label": "License Agreement (Myriad Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "5yy4wjeYgrN", "uri": "/contracts/5yy4wjeYgrN#licensed-compounds", "label": "License Agreement (Panacos Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "size": 4, "hash": "f7d6effd326062f2b7a345c98e645035", "id": 7}, {"snippet_links": [], "snippet": "means [*****].", "samples": [{"hash": "4kdd8Fd1qYT", "uri": "/contracts/4kdd8Fd1qYT#licensed-compounds", "label": "License Agreement (AC Immune SA)", "score": 30.295003891, "published": true}, {"hash": "f6w5mEjgHqw", "uri": "/contracts/f6w5mEjgHqw#licensed-compounds", "label": "License Agreement (AC Immune SA)", "score": 30.2156066895, "published": true}], "size": 4, "hash": "767337c4d203ca0b6517292d5a65f517", "id": 8}, {"snippet_links": [{"key": "schedule-b", "type": "definition", "offset": [30, 40]}], "snippet": "means the compounds listed in Schedule B, including the specific antiestrogen compound known as Acolbifene;", "samples": [{"hash": "e5NcL1DGpHW", "uri": "/contracts/e5NcL1DGpHW#licensed-compounds", "label": "Agreement (EndoCeutics, Inc.)", "score": 21.0, "published": true}, {"hash": "dkncJERk2Z9", "uri": "/contracts/dkncJERk2Z9#licensed-compounds", "label": "Agreement (EndoCeutics, Inc.)", "score": 21.0, "published": true}, {"hash": "78bKFDuiBTq", "uri": "/contracts/78bKFDuiBTq#licensed-compounds", "label": "Agreement (EndoCeutics, Inc.)", "score": 21.0, "published": true}], "size": 3, "hash": "75e0b9df85fd9dec91abca266d0bc7c1", "id": 9}, {"snippet_links": [{"key": "appendix-3", "type": "definition", "offset": [96, 106]}, {"key": "certain-information", "type": "clause", "offset": [246, 265]}, {"key": "this-exhibit", "type": "definition", "offset": [305, 317]}, {"key": "not-material", "type": "clause", "offset": [341, 353]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [363, 415]}], "snippet": "means the proprietary BMS compounds known as BMS-906024 and BMS-986115 and further described on Appendix 3, and any salt, free acid/base, solvate, hydrate, stereoisomer and polymorphic form thereof, and any prodrug, conjugate or complex thereof. Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.", "samples": [{"hash": "hIlKh1dZMqc", "uri": "/contracts/hIlKh1dZMqc#licensed-compounds", "label": "License Agreement (Immunome Inc.)", "score": 34.2313499451, "published": true}, {"hash": "cJOB1h3RMai", "uri": "/contracts/cJOB1h3RMai#licensed-compounds", "label": "License Agreement (Ayala Pharmaceuticals, Inc.)", "score": 30.3381252289, "published": true}, {"hash": "8sDIsmoJhzj", "uri": "/contracts/8sDIsmoJhzj#licensed-compounds", "label": "License Agreement (Ayala Pharmaceuticals, Inc.)", "score": 30.1765918732, "published": true}], "size": 3, "hash": "164e5ee803869bd74faa74f313c32941", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbbGljZW5zZWQtY29tcG91bmRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "title": "Licensed Compounds", "size": 220, "id": "licensed-compounds", "examples": ["If Licensee has ceased all material Development and Commercialization activities for the <strong>Licensed Compounds</strong> and Licensed Products in the Territory for [*] (such cessation for such period of time, the \u201cCessation\u201d), then Licensors may terminate this Agreement in its entirety upon [*] to Licensee.", "Any other publication or presentation relating to the <strong>Licensed Compounds</strong> and the Licensed Products by either Licensor requires [*].", "The Parties will cooperate with respect to the reporting and handling of safety information involving the <strong>Licensed Compounds</strong> and Licensed Products in accordance with Applicable Law, regulatory requirements, and regulations on pharmacovigilance and clinical safety.", "Until the [***], \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 will provide Arrowhead with a [***], summarizing the material Development activities conducted by Madrigal and its Affiliates and their respective Sublicensees with respect to the <strong>Licensed Compounds</strong> and the Licensed Products, [***].", "Promptly following the Effective Date, the Parties will negotiate and enter into a quality agreement that outlines the operational responsibilities of each Party with respect to quality assurance and quality control of the <strong>Licensed Compounds</strong> or Licensed Products supplied under this Agreement on customary and reasonable terms (the \u201cQuality Agreement\u201d).", "For clarity and without limitation of Section 3.2 (Technology and Transition Transfer Plan), upon the request of Licensee, Licensors will provide Licensee with copies of all Regulatory Materials in Licensors\u2019 possession and Control necessary to enable Licensee, its Affiliates and Sublicensees to Exploit the <strong>Licensed Compounds</strong> and Licensed Products in the Territory, including any such Regulatory Materials that are not assigned to Licensee.", "Madrigal will have sole control over and decision-making authority, at its sole cost and expense, for the Development of, and performance of Medical Affairs for, all <strong>Licensed Compounds</strong> and Licensed Products in the Field in the Territory.", "Prior to beginning work under this Agreement relating to any Development, Manufacture or Commercialization of <strong>Licensed Compounds</strong> or Licensed Products, each employee, agent, or independent contractor of Licensee or its Affiliates or Sublicensees will be bound by non-disclosure and invention assignment obligations that are consistent with the obligations of Licensee in this Section 9 (Intellectual Property), to the extent permitted by Applicable Law, including: [*].", "Each Party and its Affiliates, Sublicensees, and Subcontractors, as applicable, will conduct the Exploitation of the <strong>Licensed Compounds</strong> and the Licensed Products in a good scientific manner and materially in accordance with all applicable Laws, including, as applicable, GLP, GCP, and GMP or regulations of any Governmental Authority with jurisdiction over the activities performed by or on behalf of such Party or its Affiliates, Sublicensees or Subcontractors in furtherance of such obligations.", "Following any such regulatory inspection related to one or more <strong>Licensed Compounds</strong> or Licensed Products, Arrowhead will provide \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 [***] to the extent related to a Licensed Compound or Licensed Product within [***] after Arrowhead receives such findings, notice, or report, provided that Arrowhead may reasonably redact any such findings, notice, or report provided by the applicable Governmental Authority in respect of matter not relating to a Licensed Compound or Licensed Product."], "related": [["licensed-compound", "Licensed Compound", "Licensed Compound"], ["licensed-antibody", "Licensed Antibody", "Licensed Antibody"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["licensed-products", "Licensed Products", "Licensed Products"]], "related_snippets": [], "updated": "2026-08-06T04:42:50+00:00"}, "json": true, "cursor": ""}}